Status: Cyclacel and the University said April 20 they will study fadraciclib and seliciclib as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. Both candidates are designed to suppress Mcl-1 in patients with proliferative diseases, while seliciclib has also been shown to efficiently suppress IL-6 transcription, a presumptive contributor to COVID-19 […]

Dr. Mark Erlander, CEO of Cardiff Oncology discusses their lead drug candidate Onvansertib and the three active clinical trials in colorectal cancer, acute myeloid leukemia, and prostate cancer.  Onvansertib specifically targets and inhibits a downstream enzyme, PLK1, effectively stopping cancer cell division […]

DURHAM, N.C. (WNCN) – Durham-based Chimerix is on the fast track to saving lives of COVID-19 patients as experts learn more about deadly side effects for younger people. “We’ve essentially re-positioned the company to focus on getting this up and running in a matter of a few weeks,” said Chimerix CEO Mike Sherman. The drug DSTAT is […]